+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oncology Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery

  • ID: 5028654
  • Report
  • May 2020
  • Region: Global
  • 300 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Novartis AG
  • Takeda Pharmaceticals
  • MORE
Oncology Drugs Global Market Report 2020-30: COVID-19 Impact and Recovery from the publisher provides the strategists, marketers and senior management with the critical information they need to assess the global oncology drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the oncology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Oncology Drugs market global report from the publisher answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider oncology drugs market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The oncology drugs market section of the report gives context. It compares the oncology drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, oncology drugs indicators comparison.
Scope

Markets Covered:
1) By Type: Lung Cancer; Pancreatic Cancer; Breast Cancer; Prostate Cancer; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Kidney Cancer; Brain Tumor; Thyroid Cancer; Skin Cancer; Bladder Cancer; Cervical Cancer; Blood Cancer; Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies/ Drug Stores; Others
3) By Route Of Administration: Oral; Parenteral; Others
4) By Drug Classification: Branded Drugs; Generic Drugs
5) By Mode Of Purchase: Prescription-Based Drugs; Over-The-Counter Drugs

Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Gilead Sciences Inc; Bayer AG; Takeda Pharmaceticals

Metrics Covered: Number of Enterprises; Number of Employees

Countries: Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Colombia; Czech Republic; Denmark; Egypt; Finland; France; Germany; Hong Kong; India; Indonesia; Ireland; Israel; Italy; Japan; Malaysia; Mexico; Netherlands; New Zealand; Nigeria; Norway; Peru; Philippines; Poland; Portugal; Romania; Russia; Saudi Arabia; Singapore; South Africa; South Korea; Spain; Sweden; Switzerland; Thailand; Turkey; UAE; UK; USA; Venezuela; Vietnam

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita, oncology drugs indicators comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Novartis AG
  • Takeda Pharmaceticals
  • MORE
1. Executive Summary

2. Report Structure

3. Oncology Drugs Market Characteristics
3.1. Market Definition
3.2. Key Segmentations

4. Oncology Drugs Market Product Analysis
4.1. Leading Products/ Services
4.2. Key Features and Differentiators
4.3. Development Products

5. Oncology Drugs Market Supply Chain
5.1. Supply Chain
5.2. Distribution
5.3. End Customers

6. Oncology Drugs Market Customer Information
6.1. Customer Preferences
6.2. End Use Market Size and Growth

7. Oncology Drugs Market Trends And Strategies

8. Oncology Drugs Market Size And Growth
8.1. Market Size
8.2. Historic Market Growth, Value ($ Billion)
8.2.1. Drivers Of The Market
8.2.2. Restraints On The Market
8.3. Forecast Market Growth, Value ($ Billion)
8.3.1. Drivers Of The Market
8.3.2. Restraints On The Market

9. Oncology Drugs Market Regional Analysis
9.1. Global Oncology Drugs Market, 2019, By Region, Value ($ Billion)
9.2. Global Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Region
9.3. Global Oncology Drugs Market, Growth And Market Share Comparison, By Region

10. Oncology Drugs Market Segmentation
10.1. Global Oncology Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Lung Cancer
  • Pancreatic Cancer
  • Breast Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Kidney Cancer
  • Brain Tumor
  • Thyroid Cancer
  • Skin Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Blood Cancer
  • Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)
10.2. Global Oncology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies/ Drug Stores
  • Others
10.3. Global Oncology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Oral
  • Parenteral
  • Others
10.4. Global Oncology Drugs Market, Segmentation By Drug Classification, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Branded Drugs
  • Generic Drugs
10.5. Global Oncology Drugs Market, Segmentation By Mode Of Purchase, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Prescription-Based Drugs
  • Over-The-Counter Drugs
11. Oncology Drugs Market Metrics
11.1. Oncology Drugs Market Size, Percentage Of GDP, 2015-2023, Global
11.2. Per Capita Average Oncology Drugs Market Expenditure, 2015-2023, Global

12. Asia-Pacific Oncology Drugs Market
12.1. Asia-Pacific Oncology Drugs Market Overview
12.2. Asia-Pacific, Oncology Drugs Market, 2019, By Country, Value ($ Billion)
12.3. Asia-Pacific, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
12.4. Asia-Pacific, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
12.5. Asia-Pacific, Oncology Drugs Market Metrics
12.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2023, Asia-Pacific Countries
12.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2019, Asia-Pacific Countries
12.6. Asia-Pacific Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7. Asia-Pacific Oncology Drugs Market: Country Analysis
12.7.1. China Oncology Drugs Market
12.7.1.1. China Oncology Drugs Market Overview
12.7.1.2. China Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.1.3. China Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.2. Australia Oncology Drugs Market
12.7.2.1. Australia Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.2.2. Australia Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.3. Hong Kong Oncology Drugs Market
12.7.3.1. Hong Kong Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.4. India Oncology Drugs Market
12.7.4.1. India Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.4.2. India Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.5. Indonesia Oncology Drugs Market
12.7.5.1. Indonesia Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.5.2. Indonesia Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.6. Japan Oncology Drugs Market
12.7.6.1. Japan Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.6.2. Japan Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.7. Malaysia Oncology Drugs Market
12.7.7.1. Malaysia Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.8. New Zealand Oncology Drugs Market
12.7.8.1. New Zealand Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.9. Philippines Oncology Drugs Market
12.7.9.1. Philippines Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.10. Singapore Oncology Drugs Market
12.7.10.1. Singapore Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.11. South Korea Oncology Drugs Market
12.7.11.1. South Korea Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.11.2. South Korea Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.12. Thailand Oncology Drugs Market
12.7.12.1. Thailand Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
12.7.13. Vietnam Oncology Drugs Market
12.7.13.1. Vietnam Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

13. Western Europe Oncology Drugs Market
13.1. Western Europe Oncology Drugs Market Overview
13.2. Western Europe, Oncology Drugs Market, 2019, By Country, Value ($ Billion)
13.3. Western Europe, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
13.4. Western Europe, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
13.5. Western Europe, Oncology Drugs Market Metrics
13.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2023, Western Europe Countries
13.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2019, Western Europe Countries
13.6. Western Europe Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7. Western Europe Oncology Drugs Market: Country Analysis
13.7.1. Austria Oncology Drugs Market
13.7.1.1. Austria Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.2. Belgium Oncology Drugs Market
13.7.2.1. Belgium Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.3. Denmark Oncology Drugs Market
13.7.3.1. Denmark Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.4. Finland Oncology Drugs Market
13.7.4.1. Finland Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.5. France Oncology Drugs Market
13.7.5.1. France Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.5.2. France Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.6. Germany Oncology Drugs Market
13.7.6.1. Germany Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.6.2. Germany Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.7. Ireland Oncology Drugs Market
13.7.7.1. Ireland Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.8. Italy Oncology Drugs Market
13.7.8.1. Italy Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.9. Netherlands Oncology Drugs Market
13.7.9.1. Netherlands Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.10. Norway Oncology Drugs Market
13.7.10.1. Norway Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.11. Portugal Oncology Drugs Market
13.7.11.1. Portugal Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.12. Spain Oncology Drugs Market
13.7.12.1. Spain Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.13. Sweden Oncology Drugs Market
13.7.13.1. Sweden Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.14. Switzerland Oncology Drugs Market
13.7.14.1. Switzerland Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.15. UK Oncology Drugs Market
13.7.15.1. UK Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
13.7.15.2. UK Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

14. Eastern Europe Oncology Drugs Market
14.1. Eastern Europe Oncology Drugs Market Overview
14.2. Eastern Europe, Oncology Drugs Market, 2019, By Country, Value ($ Billion)
14.3. Eastern Europe, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
14.4. Eastern Europe, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
14.5. Eastern Europe, Oncology Drugs Market Metrics
14.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2023, Eastern Europe Countries
14.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2019, Eastern Europe Countries
14.6. Eastern Europe Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7. Eastern Europe Oncology Drugs Market: Country Analysis
14.7.1. Czech Republic Oncology Drugs Market,
14.7.1.1. Czech Republic Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7.2. Poland Oncology Drugs Market
14.7.2.1. Poland Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7.3. Romania Oncology Drugs Market
14.7.3.1. Romania Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7.4. Russia Oncology Drugs Market
14.7.4.1. Russia Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
14.7.4.2. Russia Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

15. North America Oncology Drugs Market
15.1. North America Oncology Drugs Market Overview
15.2. North America, Oncology Drugs Market, 2019, By Country, Value ($ Billion)
15.3. North America, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
15.4. North America, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
15.5. North America, Oncology Drugs Market Metrics
15.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2023, North America Countries
15.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2019, North America Countries
15.6. North America Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
15.7. North America Oncology Drugs Market: Country Analysis
15.7.1. Canada Oncology Drugs Market
15.7.1.1. Canada Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
15.7.2. Mexico Oncology Drugs Market
15.7.2.1. Mexico Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
15.7.3. USA Oncology Drugs Market
15.7.3.1. USA Oncology Drugs Market Overview
15.7.3.2. USA Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
15.7.3.3. USA Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

16. South America Oncology Drugs Market
16.1. South America Oncology Drugs Market Overview
16.2. South America, Oncology Drugs Market, 2019, By Country, Value ($ Billion)
16.3. South America, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
16.4. South America, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
16.5. South America, Oncology Drugs Market Metrics
16.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2023, South America Countries
16.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2019, South America Countries
16.6. South America Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7. South America Oncology Drugs Market: Country Analysis
16.7.1. Argentina Oncology Drugs Market
16.7.1.1. Argentina Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.2. Brazil Oncology Drugs Market
16.7.1.1. Brazil Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.2.2. Brazil Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.3. Chile Oncology Drugs Market
16.7.3.1. Chile Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.4. Colombia Oncology Drugs Market
16.7.4.1. Colombia Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.5. Peru Oncology Drugs Market
16.7.5.1. Peru Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
16.7.6. Venezuela Oncology Drugs Market
16.7.6.1. Venezuela Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

17. Middle East Oncology Drugs Market
17.1. Middle East Oncology Drugs Market Overview
17.2. Middle East, Oncology Drugs Market, 2019, By Country, Value ($ Billion)
17.3. Middle East, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
17.4. Middle East, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
17.5. Middle East, Oncology Drugs Market Metrics
17.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2023, Middle East Countries
17.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2019, Middle East Countries
17.6. Middle East Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
17.7. Middle East Oncology Drugs Market: Country Analysis
17.7.1. Saudi Arabia Oncology Drugs Market
17.7.1.1. Saudi Arabia Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
17.7.2. Israel Oncology Drugs Market
17.7.2.1. Israel Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
17.7.3. Turkey Oncology Drugs Market
17.7.3.1. Turkey Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
17.7.4. UAE Oncology Drugs Market
17.7.4.1. UAE Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

18. Africa Oncology Drugs Market
18.1. Africa Oncology Drugs Market Overview
18.2. Africa, Oncology Drugs Market, 2019, By Country, Value ($ Billion)
18.3. Africa, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Country
18.4. Africa, Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Growth And Market Share Comparison, By Country
18.5. Africa, Oncology Drugs Market Metrics
18.5.1. Per Capita Average Oncology Drugs Expenditure, 2015-2023, Africa Countries
18.5.2. Cancer Prevalence Rate, Oncology Drugs Market, Oncology Drugs Market/Cancer Prevalence Rate, 2019, Africa Countries
18.6. Africa Oncology Drugs Market, Segmentation By Type, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
18.7. Africa Oncology Drugs Market: Country Analysis
18.7.1. Egypt Oncology Drugs Market
18.7.1.1. Egypt Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
18.7.2. Nigeria Oncology Drugs Market
18.7.2.1. Nigeria Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)
18.7.3. South Africa Oncology Drugs Market
18.7.3.1. South Africa Oncology Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Value ($ Billion)

19. Oncology Drugs Market Competitive Landscape
19.1. Competitive Market Overview
19.2. Market Shares
19.3. Company Profiles
19.3.1. F. Hoffmann-La Roche Ltd
19.3.1.1. Company Overview
19.3.1.2. Products And Services
19.3.1.3. Strategy
19.3.1.4. Financial Performance
19.3.2. Novartis AG
19.3.2.1. Company Overview
19.3.2.2. Products And Services
19.3.2.3. Strategy
19.3.2.4. Financial Performance
19.3.3. Gilead Sciences Inc
19.3.3.1. Company Overview
19.3.3.2. Products And Services
19.3.3.3. Strategy
19.3.3.4. Financial Performance
19.3.4. Bayer AG
19.3.4.1. Company Overview
19.3.4.2. Products And Services
19.3.4.3. Strategy
19.3.4.4. Financial Performance
19.3.5. Takeda Pharmaceticals
19.3.5.1. Company Overview
19.3.5.2. Products And Services
19.3.5.3. Strategy
19.3.5.4. Financial Performance

20. Key Mergers And Acquisitions In The Oncology Drugs Market

21. Market Background: Pharmaceutical Drugs Market
21.1. Pharmaceutical Drugs Market Characteristics
21.2. Pharmaceutical Drugs Market Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F Growth, By Segment, Value ($ Billion), Global
21.3. Global Pharmaceutical Drugs Market, 2019, By Region, Value ($ Billion)
21.4. Global Pharmaceutical Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Historic And Forecast, By Region
21.5. Global Pharmaceutical Drugs Market, 2015-2019, 2023F, 2025F, 2030F, Segmentation By Type, Value ($ Billion)

22. Recommendations
22.1. Global Oncology Drugs Market In 2023- Growth Countries
22.2. Global Oncology Drugs Market In 2023- Growth Segments
22.3. Global Oncology Drugs Market In 2023- Growth Strategies

23. Appendix
23.1. NAICS Definitions Of Industry Covered In This Report
23.2. Abbreviations
23.3. Currencies
23.4. Research Inquiries
23.5. About the Publisher

24. Copyright And Disclaimer
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences Inc
  • Novartis AG
  • Takeda Pharmaceticals
  • MORE
North America was the largest region in the global oncology drugs market, accounting for 35% of the market in 2019. Asia Pacific was the second largest region accounting for 34% of the global oncology drugs market. Africa was the smallest region in the global oncology drugs market.

Companies are increasingly using cancer biomarkers in the drug development process. Cancer biomarkers are molecules secreted by a tumor or a specific response of the body to the presence of cancer. Identifying and targeting these can enhance cancer detection and facilitate high-speed noninvasive diagnosis using genomics and proteomics tools. It can also help predict the drug efficacy faster than conventional clinical endpoints, the point at which an undesired or abnormal effect of the drug is observed indicating withdrawal from therapy. Companies in this market are investing in the development of biomarkers for use in various activities such as tracking drug activity, the pharmacodynamics of drugs and to study diseases and treatment pathways. For instance, Nektar Therapeutics is developing and using biomarkers in drug development processes of its pipeline drugs NKTR-214 and NKTR-181. Janssen’s research & development is also focusing on identifying predictive markers or stratification markers to help target the new therapies.

The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types.

The global oncology drugs market is expected to decline from $84.4 billion in 2019 to $75.5 billion in 2020 at a compound annual growth rate (CAGR) of -10.6%. The decline is mainly due to the COVID-19 outbreak and the measures to contain it. Hospitals across the world have postponed the chemo treatments for cancer patients due to COVID positive cases in the hospitals. The sessions are delayed or postponed to prevent patients and staff from unnecessary exposure. The cancer treatment can lower the patient's ability to fight infection. COVID-19 pandemic is affecting industries across the globe including the pharmaceutical sector. The disruptions due to extended factory closures in various countries, shortage of APIs and other chemicals, rise in prices of key ingredients, and slowed production are the key factors for this decline. The market is then expected to recover and grow at a CAGR of 8% from 2021 and reach $113.7 billion in 2023.
Note: Product cover images may vary from those shown
4 of 5
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Gilead Sciences Inc
  • Bayer AG
  • Takeda Pharmaceticals
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll